New Century Financial Group LLC Buys New Position in DENTSPLY SIRONA Inc. $XRAY

Key Points

• New Century Financial Group LLC purchased 71,093 shares of DENTSPLY SIRONA Inc., amounting to approximately $1,129,000, which represents 1.3% of its investment portfolio.
• Several institutional investors, including AQR Capital Management and Goldman Sachs Group, significantly increased their stakes in DENTSPLY SIRONA during the first quarter of this year, contributing to a total institutional ownership of 95.70%.
• DENTSPLY SIRONA recently announced a quarterly dividend of $0.16 per share, yielding 4.9%, with the ex-dividend date set for September 26th.

New Century Financial Group LLC bought a new stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 71,093 shares of the medical instruments supplier's stock, valued at approximately $1,129,000. DENTSPLY SIRONA makes up about 1.3% of New Century Financial Group LLC's investment portfolio, making the stock its 29th largest position.

Other hedge funds and other institutional investors have also modified their holdings of the company. AQR Capital Management LLC raised its position in shares of DENTSPLY SIRONA by 119.4% in the first quarter. AQR Capital Management LLC now owns 6,346,685 shares of the medical instruments supplier's stock valued at $93,423,000 after buying an additional 3,453,662 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of DENTSPLY SIRONA by 827.3% during the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier's stock worth $36,378,000 after purchasing an additional 2,172,343 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in shares of DENTSPLY SIRONA by 11.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 13,961,759 shares of the medical instruments supplier's stock valued at $208,590,000 after purchasing an additional 1,412,517 shares during the period. Ninety One UK Ltd acquired a new position in DENTSPLY SIRONA in the second quarter valued at $18,418,000. Finally, Edmond DE Rothschild Holding S.A. lifted its position in DENTSPLY SIRONA by 26.4% during the first quarter. Edmond DE Rothschild Holding S.A. now owns 2,913,400 shares of the medical instruments supplier's stock worth $43,526,000 after buying an additional 609,300 shares during the period. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Wells Fargo & Company lowered their price target on DENTSPLY SIRONA from $16.00 to $15.00 and set an "equal weight" rating for the company in a report on Friday, August 8th. UBS Group lowered their target price on shares of DENTSPLY SIRONA from $25.00 to $24.00 and set a "buy" rating for the company in a report on Friday, August 8th. Needham & Company LLC reaffirmed a "hold" rating on shares of DENTSPLY SIRONA in a research note on Friday, September 26th. Stifel Nicolaus lowered their price objective on shares of DENTSPLY SIRONA from $19.00 to $17.00 and set a "hold" rating for the company in a research note on Friday, August 8th. Finally, Wall Street Zen upgraded DENTSPLY SIRONA from a "hold" rating to a "buy" rating in a report on Friday, September 26th. Two research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $18.64.

DENTSPLY SIRONA Stock Performance

Shares of DENTSPLY SIRONA stock opened at $12.96 on Friday. The firm has a market cap of $2.59 billion, a PE ratio of -2.73, a price-to-earnings-growth ratio of 0.81 and a beta of 0.96. DENTSPLY SIRONA Inc. has a 1 year low of $12.14 and a 1 year high of $25.23. The firm's 50-day simple moving average is $13.85 and its 200-day simple moving average is $14.74. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.11 and a current ratio of 1.69.

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.50 by $0.02. The company had revenue of $936.00 million for the quarter, compared to the consensus estimate of $929.67 million. DENTSPLY SIRONA had a positive return on equity of 16.33% and a negative net margin of 25.85%.DENTSPLY SIRONA's quarterly revenue was down 4.9% compared to the same quarter last year. During the same quarter last year, the business posted $0.49 EPS. DENTSPLY SIRONA has set its FY 2025 guidance at 1.800-2.000 EPS. Equities analysts forecast that DENTSPLY SIRONA Inc. will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 10th. Shareholders of record on Friday, September 26th will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 4.9%. The ex-dividend date of this dividend is Friday, September 26th. DENTSPLY SIRONA's payout ratio is currently -13.50%.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.